Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 82.35

-4.5%

Jan 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2754)	6/2/2010 11:40:07 AM
From: Jibacoa	Read Replies (1) of 3722

GENT reached my target of $5 in April and traded at $5.86 on April 19 <g> Today the stock is down and is presently testing support at yesterday's L of $4.41. It seems it may come down to the $4.20 level as it needs to regroup before it is able to go through the $5 resistance again. bigcharts.marketwatch.com Last week it reported its 1stQ results, which showed a good increase in revenues and it reported earnings on the black at $0.08 vs. loss of $0.27 in 2009 This is the 3rd time that GENT has reported better revenues, which have also shown sequential improvement. GENT was cash flow positive at the end of the 1stQ and said that it expects to remain cash flows positive/neutral throughout 2010 <g> I took profits in April, but plan on buying back some shares if GENT can close above $5 They still need to complete certain preclinical and clinical studies before they are able to file a new NDA for Defibrotide. <g> The ACTAY is $5 But with some good news and a close above $5 I will place a target at $10. As always, it is better to keep a trailing stop loss.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next